{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:42:52Z","timestamp":1776919372134,"version":"3.51.2"},"reference-count":51,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Immunocompromised children undergoing chemotherapy or allogeneic hematopoietic stem cell transplantation (HSCT) for hematologic disorders face a high risk of serious, life-threatening infections caused by multidrug-resistant (MDR) bacteria. Cefiderocol is a novel siderophore cephalosporin, indicated for use in adult patients with MDR Gram-negative infections. Clinical data in immunocompromised children are limited. To report a multicenter real-life experience from the Infection Working Group of the Italian Pediatric Hematology and Oncology Association (IWG-AIEOP) on the use of cefiderocol in treating pediatric onco-hematologic patients with severe, high-risk infections. Methods: Multicenter retrospective collection of infectious episodes treated with cefiderocol, from January 2021 to December 2024, in patients 18 years or younger, after treatment for malignancies or undergoing HSCT in the AIEOP network, part of a prospective, observational study on the etiology and outcome of febrile episodes among 24 AIEOP centers (code NCT06419426). Results: Fifteen episodes of MDR, life-threatening Gram-negative infections treated with cefiderocol in 13 pediatric onco-hematologic patients were collected. There were eight males and five females, mainly affected by acute leukemia (six lymphoblastic and four myeloid, three other hematologic malignancies). The median age was 11.1 years (range 1\u201317.4 years), and the median weight was 37.8 kg (range 8\u201365). Bloodstream infection occurred in 10 of 15 episodes. Pseudomonas aeruginosa, Klebsiella pneumoniae, and Stenotrophomonas maltophilia were isolated in 11, 3, and 1 episodes, respectively. Notably, 11 of 15 isolated pathogens carried a metallo-beta-lactamase (MBL) gene (Verona integron-encoded, VIM, n = 10; New Delhi, NDM, n = 1). All patients achieved infection resolution and were alive and infection-free 90 days after infection onset. Conclusions: Cefiderocol was well tolerated and showed encouraging, favorable clinical outcomes, without serious adverse effects.<\/jats:p>","DOI":"10.3390\/jcm15083100","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T08:24:23Z","timestamp":1776673463000},"page":"3100","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cefiderocol in Children with Hematologic Malignancies\u2014The Multicenter Retrospective Experience of the Infection Working Group of the Italian Pediatric Hematology and Oncology Association (AIEOP)"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8813-3200","authenticated-orcid":false,"given":"Paola","family":"Muggeo","sequence":"first","affiliation":[{"name":"U.O.C. Pediatria ad Indirizzo Oncoematologico, Azienda Ospedaliero Universitaria Consorziale Policlinico, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Galaverna","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Hematology, Cell and Gene Therapy, IRCCS Bambino Ges\u00f9 Pediatric Hospital, 00165 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9633-873X","authenticated-orcid":false,"given":"Lorenzo","family":"Chiusaroli","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department for Women\u2019s and Children\u2019s Health, University of Padua, 35128 Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Perruccio","sequence":"additional","affiliation":[{"name":"Oncoematologia Pediatrica, Ospedale Santa Maria della Misericordia, 06129 Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Coccia","sequence":"additional","affiliation":[{"name":"Oncoematologia Pediatrica, Presidio Ospedaliero \u201cG. Salesi\u201d, 60123 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8313-7288","authenticated-orcid":false,"given":"Francesco","family":"Baccelli","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), University of Bologna, 40126 Bologna, Italy"},{"name":"Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40126 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Boccieri","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Hematology, Cell and Gene Therapy, IRCCS Bambino Ges\u00f9 Pediatric Hospital, 00165 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Rosignoli","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Hematology, Cell and Gene Therapy, IRCCS Bambino Ges\u00f9 Pediatric Hospital, 00165 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"De Leonardis","sequence":"additional","affiliation":[{"name":"U.O.C. Pediatria ad Indirizzo Oncoematologico, Azienda Ospedaliero Universitaria Consorziale Policlinico, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8853-6536","authenticated-orcid":false,"given":"Nicola","family":"Santoro","sequence":"additional","affiliation":[{"name":"U.O.C. Pediatria ad Indirizzo Oncoematologico, Azienda Ospedaliero Universitaria Consorziale Policlinico, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8698-9547","authenticated-orcid":false,"given":"Simone","family":"Cesaro","sequence":"additional","affiliation":[{"name":"Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Univeritaria Integrata, 37126 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024). WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s10096-024-05034-z","article-title":"Evolution of ceftazidime\/avibactam resistance and plasmid dynamics in OXA-48-producing Klebsiella spp. during long-term patient colonization","volume":"44","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"106380","DOI":"10.1016\/j.jinf.2024.106380","article-title":"Distributions of plasmidic genes encoding extended-spectrum and AmpC \u03b2-lactamases, and susceptibilities of global non-carbapenemase-producing meropenem-resistant Enterobacterales to ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam-avibactam, 2017\u20132022","volume":"90","author":"Jean","year":"2025","journal-title":"J. Infect."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Venuti, F., Romani, L., De Luca, M., Tripiciano, C., Palma, P., Chiriaco, M., Finocchi, A., and Lancella, L. (2023). Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review. Microorganisms, 11.","DOI":"10.3390\/microorganisms11071798"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(20)30725-7","article-title":"8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation","volume":"22","author":"Lehrnbecher","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e00256-20","DOI":"10.1128\/JCM.00256-20","article-title":"What\u2019s Special about Cefiderocol? A Micro-Comic Strip","volume":"58","author":"Simner","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J., and Bonomo, R.A. (2024). Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin. Infect. Dis., ciae403.","DOI":"10.1093\/cid\/ciae403"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e01454-17","DOI":"10.1128\/AAC.01454-17","article-title":"In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria","volume":"62","author":"Ito","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ejmech.2018.06.014","article-title":"Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship","volume":"155","author":"Aoki","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10096-021-04341-z","article-title":"In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: Cross-resistance and synergistic effects","volume":"41","author":"Bianco","year":"2022","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e0271221","DOI":"10.1128\/spectrum.02712-21","article-title":"In Vitro Activity of Cefiderocol against, U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program","volume":"10","author":"Shortridge","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1093\/jac\/dkad200","article-title":"In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014\u20132019)","volume":"78","author":"Takemura","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2200795","DOI":"10.2807\/1560-7917.ES.2022.27.43.2200795","article-title":"Nosocomial outbreak by NDM-1-producing Klebsiella pneumoniae highly resistant to cefiderocol, Florence, Italy, August 2021 to June 2022","volume":"27","author":"Coppi","year":"2022","journal-title":"Eurosurveillance"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): A randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/cid\/ciac078","article-title":"Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies","volume":"75","author":"Timsit","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"ofae631.1645","DOI":"10.1093\/ofid\/ofae631.1645","article-title":"P-1475. Real-World Effectiveness and Safety of Cefiderocol in the Treatment of Patients with Serious Gram-negative Bacterial Infections: Results of the PROVE Chart Review Study","volume":"12","author":"Clancy","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e01872-19","DOI":"10.1128\/AAC.01872-19","article-title":"Long-Term Compassionate Use of Cefiderocol to Treat Chronic Osteomyelitis Caused by Extensively Drug-Resistant Pseudomonas aeruginosa and Extended-Spectrum-\u03b2-Lactamase-Producing Klebsiella pneumoniae in a Pediatric Patient","volume":"64","author":"Alamarat","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40121-022-00735-4","article-title":"Bloodstream Infection Due to a VIM-Metallo-\u03b2-Lactamase-Producing Klebsiella pneumoniae Treated with Cefiderocol in a Preterm Newborn","volume":"12","author":"Monari","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"ofad174","DOI":"10.1093\/ofid\/ofad174","article-title":"Successful Treatment of Persistent Stenotrophomonas maltophilia Bacteremia with Cefiderocol in an Infant","volume":"10","author":"Hsu","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Mercadante, S., Tripiciano, C., Romani, L., Di Nardo, M., Bottari, G., Goffredo, B.M., Simeoli, R., Guzzo, I., Lancella, L., and Antachopoulos, C. (2023). The Use of Cefiderocol as Salvage Therapy in an Infant Receiving ECMO and Continuous Renal Replacement Therapy. Antibiotics, 13.","DOI":"10.3390\/antibiotics13010037"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1097\/INF.0000000000004051","article-title":"Successful Use of Cefiderocol to Treat a Multidrug-resistant Stenotrophomonas maltophilia Ventilator-associated Pneumonia in an Extremely Preterm Neonate","volume":"42","author":"Koirala","year":"2023","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/INF.0000000000004347","article-title":"Use of Cefiderocol in the Management of Children with Infection or Colonization with Multi-drug Resistant Gram-negative Bacteria: A Retrospective, Single-center Case Series","volume":"43","author":"Schmid","year":"2024","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jgar.2021.04.025","article-title":"Compassionate use of cefiderocol for VIM metallo-\u03b2-lactamase-producing Pseudomonas aeruginosa infection in a toddler with Burkitt lymphoma","volume":"26","author":"Grasa","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"116539","DOI":"10.1016\/j.diagmicrobio.2024.116539","article-title":"Cefiderocol as rescue therapy in a cancer immunosuppressed critically ill child: Case description and literature review","volume":"110","year":"2024","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/INF.0000000000004529","article-title":"Pharmacokinetics, Safety and Tolerability of Single-dose or Multiple-dose Cefiderocol in Hospitalized Pediatric Patients Three Months to Less Than Eighteen Years Old with Infections Treated with Standard-of-care Antibiotics in the PEDI-CEFI Phase 2 Study","volume":"44","author":"Bradley","year":"2025","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_27","unstructured":"(2026, March 25). Available online: https:\/\/www.epicentro.iss.it\/antibiotico-resistenza\/linee-guida-manuale-ministero-2020."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"106376","DOI":"10.1016\/j.jinf.2024.106376","article-title":"Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant Gram-negative bacteria: CEFI-ID","volume":"90","author":"Soueges","year":"2025","journal-title":"J. Infect."},{"key":"ref_29","unstructured":"World Health Organization (2023). Paediatric Drug Optimization for Antibiotics: Meeting Report, 30 November, 5\u20137 December 2022."},{"key":"ref_30","unstructured":"(2026, February 05). Cefiderocol Injection, Available online: https:\/\/www.fda.gov\/drugs\/development-resources\/cefiderocol-injection."},{"key":"ref_31","unstructured":"(2026, February 05). European Medicines Agency. Fetcroja. Cefiderocol. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fetcroja."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/14656566.2025.2519690","article-title":"Tackling multidrug-resistant Gram-negative infections in children globally: Current therapeutic options and perspectives","volume":"26","author":"Chiusaroli","year":"2025","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"piaf004","DOI":"10.1093\/jpids\/piaf004","article-title":"Suggested Dosing of Select Beta-lactam Agents for the Treatment of Antimicrobial-Resistant Gram-Negative Infections in Children","volume":"14","author":"Lockowitz","year":"2025","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/INF.0000000000004150","article-title":"Cefiderocol Red Wine Urine Syndrome in Pediatric Patients: A Multicenter Case Series","volume":"43","author":"Shapiro","year":"2024","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Lin, H., Zhu, C., Liu, S., Bi, Y., Hu, J., and Ju, M. (2025). Post-market safety profile of cefiderocol: A real-world pharmacovigilance exploratory analysis based on U.S. FDA adverse event reporting system (FAERS). BMC Pharmacol. Toxicol., 26.","DOI":"10.1186\/s40360-025-00894-3"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s10096-025-05108-6","article-title":"Effectiveness and safety of cefiderocol treatment in patients with Gram-negative bacterial infections in Spain in the early access programme: Results of the PERSEUS study","volume":"44","author":"Almirante","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.3855\/jidc.19875","article-title":"Efficacy and safety of cefiderocol in the treatment of infections caused by Gram-negative bacteria: A systematic review and meta-analysis","volume":"18","author":"Huang","year":"2024","journal-title":"J. Infect. Dev. Ctries."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Verras, G.I., and Mulita, F. (2024). Butyrylcholinesterase levels correlate with surgical site infection risk and severity after colorectal surgery: A prospective single-center study. Front. Surg., 11.","DOI":"10.3389\/fsurg.2024.1379410"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Ding, Z., Sun, Z., and Zhong, Q. (2025). Analysis of the association between cholinesterase and in-hospital mortality in children with bloodstream infections in the pediatric intensive care unit. Front. Pediatr., 13.","DOI":"10.3389\/fped.2025.1588634"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"107560","DOI":"10.1016\/j.micpath.2025.107560","article-title":"An assessment of cefiderocol\u2019s synergistic effects with eravacycline, colistin, meropenem, levofloxacin, ceftazidime\/avibactam, and tobramycin against carbapenem-resistant and -susceptible Pseudomonas aeruginosa","volume":"204","author":"Yilmaz","year":"2025","journal-title":"Microb. Pathog."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10096-024-04994-6","article-title":"In-vitro activity of the novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022","volume":"44","author":"Bouvier","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"107407","DOI":"10.1016\/j.ijantimicag.2024.107407","article-title":"In vitro antimicrobial activity of six novel \u03b2-lactam and \u03b2-lactamase inhibitor combinations and cefiderocol against NDM-producing Enterobacterales in China","volume":"65","author":"Liu","year":"2025","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jac\/dkae367","article-title":"Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: Are we already losing cefiderocol?","volume":"80","author":"Baltas","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jiph.2024.02.006","article-title":"Reduce susceptibility to cefiderocol in gram negative bacteria in children: Is hope already lost before it\u2019s even arrived?","volume":"17","author":"Russo","year":"2024","journal-title":"J. Infect. Public Health"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"106417","DOI":"10.1016\/j.jinf.2025.106417","article-title":"Zidebactam restores cefiderocol sensitivity in resistant bacteria","volume":"90","author":"Xu","year":"2025","journal-title":"J. Infect."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.cmi.2024.11.006","article-title":"Aztreonam and avibactam combination therapy for metallo-\u03b2-lactamase-producing gram-negative bacteria: A Narrative Review","volume":"31","author":"Sangiorgio","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_47","unstructured":"(2026, March 20). CDC Infection Control. Epidemiology of MDRO, Available online: https:\/\/www.cdc.gov\/infection-control\/hcp\/mdro-management\/epidemiology.html#cdc_generic_section_3-role-of-colonized-hcp-in-mdro-transmission."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.cmi.2019.01.005","article-title":"ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers","volume":"25","author":"Tacconelli","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jinf.2022.04.028","article-title":"Fecal microbiota transplantation for Carbapenem-Resistant Enterobacteriaceae: A systematic review","volume":"84","author":"Dong","year":"2022","journal-title":"J. Infect."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1093\/jac\/dkaf391","article-title":"The Achilles\u2019 heel of the Trojan Horse? A systematic evaluation of cefiderocol susceptibility testing","volume":"80","author":"Tsakri","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_51","unstructured":"(2026, March 25). WHO Model List of Essential Medicines\u201423rd List, 2023. Available online: https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2023.04."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/8\/3100\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:14:42Z","timestamp":1776917682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/8\/3100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":51,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jcm15083100"],"URL":"https:\/\/doi.org\/10.3390\/jcm15083100","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]}}}